Related Experiment Video
Updated: Apr 12, 2026
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
Target therapy in metastatic pheochromocytoma: current perspectives and controversies
Amrallah A Mohammed1, Ayman M El-Shentenawy2, Mohamed A Sherisher3
1Oncology Center, King Abdullah Medical City-Holy Capital , Saudi Arabia ; Medical Oncology Department, Zagazig University , Egypt.
Abstract:
Most of the pheochromocytomas (PCCs) are benign neoplasms, but when they are malignant, they can be difficult to treat. Despite advances in diagnosis and imaging, it remains an untreatable tumor, when metastases develop. A deeper understanding of the alteration of the specific molecular pathways causing malignant PCCs might hopefully lead in the future to the development of multiple molecular-targeted therapies to treat it successfully. Clinical experience and the use of murine models of metastatic PCCs have helped introduce new experimental treatment options which will significantly help the PCCs community explore novel targeted therapies that have already shown promising results in many other types of tumors.
Insights
Malignant pheochromocytomas (PCCs) are challenging to treat, especially with metastasis. Understanding their molecular pathways could unlock new targeted therapies for this rare tumor.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pheochromocytomas (PCCs) are rare tumors, mostly benign, but malignant forms with metastasis are difficult to treat.
- Current diagnostic and imaging techniques have limitations in managing advanced malignant PCCs.
Purpose of the Study:
- To explore the molecular alterations driving malignant pheochromocytomas (PCCs).
- To identify potential molecular targets for novel, effective therapies against metastatic PCCs.
Main Methods:
- Review of clinical data and experience with metastatic PCCs.
- Utilizing murine models to study PCC progression and treatment responses.
Main Results:
- Emerging experimental treatments show promise in preclinical models.
- Focus on understanding specific molecular pathways is crucial for therapeutic development.
Conclusions:
- Further research into the molecular basis of malignant PCCs is essential.
- Targeted therapies, informed by molecular pathway analysis, offer future treatment hope for metastatic PCCs.
